GSK revenue and financials
Secondary listing. The primary listing is GSK · LSE (GBp)
$46.60Change from previous close: +0.11%Absolute change: +$0.05
In the fiscal year ended December 2025, GSK reported revenue of £32.67B (+4.11% year over year). Net income was £5.72B, a net margin of 17.5%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +4.11%
- 2025 vs 2024
- Net income growth
- +121.98%
- 2025 vs 2024
- Net margin
- 17.5%
- 2024: 8.2%
Financial data
Amounts in millions of GBP; per-share values in GBP; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 8,409 | 7,629 | 8,618 | 8,547 | 7,986 | 7,516 | 8,117 | 8,012 | 7,884 | 7,363 | 8,052 | 8,147 |
| Cost of revenue | 2,072 | 1,873 | 2,617 | 2,239 | 2,165 | 1,926 | 2,537 | 2,328 | 2,062 | 1,918 | 2,337 | 2,243 |
| Gross profit | 6,337 | 5,756 | 6,001 | 6,308 | 5,821 | 5,590 | 5,580 | 5,684 | 5,822 | 5,445 | 5,715 | 5,904 |
| Selling, general and administrative | 2,192 | 2,085 | 2,666 | 2,162 | 2,131 | 2,054 | 2,621 | 3,767 | 2,389 | 2,070 | 2,595 | 2,212 |
| Research and development | 1,747 | 1,518 | 2,138 | 1,575 | 1,544 | 1,397 | 1,836 | 1,441 | 1,428 | 1,373 | 1,799 | 1,448 |
| Operating income | 2,602 | 2,768 | 1,631 | 3,082 | 2,392 | 2,310 | 1,003 | 667 | 2,149 | 2,305 | 1,721 | 2,765 |
| EBIT | 2,602 | 2,768 | 1,631 | 3,082 | 2,392 | 2,310 | 1,003 | 667 | 2,149 | 2,305 | 1,721 | 2,765 |
| EBITDA | 2,825 | 3,231 | 2,689 | 3,820 | 3,011 | 3,133 | 1,849 | 1,618 | 2,788 | 2,854 | 1,951 | 3,344 |
| Interest expense | 182 | 167 | 145 | 167 | 184 | 162 | 120 | 155 | 174 | 166 | 146 | 180 |
| Pre-tax income | 354 | 2,144 | 950 | 2,456 | 1,887 | 2,108 | 563 | 64.0 | 1,495 | 1,355 | 379 | 1,791 |
| Income tax | -199 | 305 | 223 | 312 | 241 | 336 | 62.0 | -1.0 | 191 | 274 | -19.0 | 257 |
| Net income | 435 | 1,737 | 636 | 2,013 | 1,443 | 1,624 | 414 | -58.0 | 1,173 | 1,046 | 350 | 1,464 |
| Net income to common shareholders | 435 | 1,737 | 636 | 2,013 | 1,443 | 1,624 | 414 | -58.0 | 1,173 | 1,046 | 350 | 1,464 |
| Basic EPS | 0.11 | 0.43 | 0.16 | 0.50 | 0.36 | 0.40 | 0.10 | -0.01 | 0.29 | 0.26 | 0.09 | 0.36 |
| Diluted EPS | 0.11 | 0.43 | 0.16 | 0.49 | 0.35 | 0.39 | 0.10 | -0.01 | 0.29 | 0.25 | 0.09 | 0.36 |
| Average shares (basic) | 4,014 | 4,023 | 4,019 | 4,034 | 4,063 | 4,088 | 4,081 | 4,080 | 4,079 | 4,069 | 4,056 | 4,055 |
| Average shares (diluted) | 4,062 | 4,074 | 4,086 | 4,102 | 4,110 | 4,137 | 4,145 | 4,141 | 4,122 | 4,113 | 4,116 | 4,112 |
| Dividend per share | 0.17 | 0.17 | 0.18 | 0.16 | 0.16 | 0.16 | 0.16 | 0.15 | 0.15 | 0.15 | 0.16 | 0.14 |